Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12153017 | 0.82 | CXCR2 (0.45) | CXCR2CXCR1 | |
| SCHEMBL1487157 | 0.81 | CXCR2 (0.40) | CXCR2CXCR1 | |
| SCHEMBL1487149 | 0.81 | CXCR2 (0.41) | CXCR2CXCR1 | |
| SCHEMBL1487212 | 0.80 | CXCR2 (0.64) | CXCR2CXCR1 | |
| SCHEMBL1487141 | 0.80 | CXCR2 (0.53) | CXCR2CXCR1 | |
| SCHEMBL1487137 | 0.80 | CXCR2 (0.53) | CXCR2CXCR1 | |
| SCHEMBL1803298 | 0.78 | CXCR2 (0.62) | CXCR2CXCR1 | |
| SCHEMBL1487018 | 0.78 | CXCR2 (0.46) | CXCR2CXCR1 | |
| SCHEMBL1487064 | 0.78 | CXCR2 (0.46) | CXCR2CXCR1 | |
| SCHEMBL1804986 | 0.77 | CXCR2 (0.46) | CXCR2CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8269002-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2012-09-18 | — | — | US | disclosed |
| US-20110124619-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124619-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | CXCR2 4/4885CXCR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.